| Year |
Citation |
Score |
| 2023 |
Wagner BD, Zemanick ET, Sagel SD, Robertson CE, Stevens MJ, Mayer-Hamblett N, Retsch-Bogart G, Ramsey BW, Harris JK. Limited effects of azithromycin on the oropharyngeal microbiome in children with CF and early pseudomonas infection. Bmc Microbiology. 23: 312. PMID 37891457 DOI: 10.1186/s12866-023-03073-8 |
0.342 |
|
| 2022 |
Pittman JE, Skalland MS, Sagel SD, Ramsey BW, Mayer-Hamblett N, Retsch-Bogart GZ. Impact of azithromycin on serum inflammatory markers in children with cystic fibrosis and new Pseudomonas. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 35260354 DOI: 10.1016/j.jcf.2022.02.015 |
0.329 |
|
| 2021 |
Nichols DP, Singh PK, Baines A, Caverly LJ, Chmiel JF, GIbson RL, Lascano J, Morgan SJ, Retsch-Bogart G, Saiman L, Sadeghi H, Billings JL, Heltshe SL, Kirby S, Kong A, et al. Testing the effects of combining azithromycin with inhaled tobramycin for in cystic fibrosis: a randomised, controlled clinical trial. Thorax. PMID 34706982 DOI: 10.1136/thoraxjnl-2021-217782 |
0.322 |
|
| 2021 |
Stanojevic S, Davis SD, Perrem L, Shaw M, Retsch-Bogart G, Davis M, Jensen R, Clem CC, Isaac SM, Guido J, Jara S, France L, McDonald N, Solomon M, Sweezey N, et al. Determinants of lung disease progression measured by lung clearance index in children with cystic fibrosis. The European Respiratory Journal. PMID 33542049 DOI: 10.1183/13993003.03380-2020 |
0.351 |
|
| 2020 |
Mayer-Hamblett N, van Koningsbruggen-Rietschel S, Nichols DP, VanDevanter DR, Davies JC, Lee T, Durmowicz AG, Ratjen F, Konstan MW, Pearson K, Bell SC, Clancy JP, Taylor-Cousar JL, De Boeck K, Donaldson SH, ... ... Retsch-Bogart GZ, et al. Building global development strategies for cf therapeutics during a transitional cftr modulator era. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 32522463 DOI: 10.1016/J.Jcf.2020.05.011 |
0.399 |
|
| 2020 |
Perrem L, Stanojevic S, Shaw M, Davis S, Retsch-Bogart G, Ratjen F. Changes in the parent cystic fibrosis questionnaire-revised (CFQ-R) with respiratory symptoms in preschool children with cystic fibrosis. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 32139196 DOI: 10.1016/J.Jcf.2020.02.017 |
0.406 |
|
| 2019 |
Miranda C, Cardenas M, Bedoya M, Retsch-Bogart G, Colin AA. Nonsystemic allergic bronchopulmonary aspergillosis in cystic fibrosis: A suggested paradigm for the evolution from topical to systemic disease. Pediatric Pulmonology. PMID 30938080 DOI: 10.1002/Ppul.24325 |
0.415 |
|
| 2019 |
Reix P, Klingel M, Davis S, Retsch-Bogart G, Stanojevic S, Ratjen F. WS07-3 Effect of cumulative bacterial infection on the Lung Clearance Index in preschool children with cystic fibrosis Journal of Cystic Fibrosis. 18: S13. DOI: 10.1016/S1569-1993(19)30156-0 |
0.458 |
|
| 2018 |
Retsch-Bogart G, Mayer-Hamblett N, Ramsey BW. Reply to: Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis; Do the Benefits Outweigh the Harms? American Journal of Respiratory and Critical Care Medicine. PMID 30138567 DOI: 10.1164/Rccm.201808-1462Le |
0.432 |
|
| 2018 |
Mayer-Hamblett N, Retsch-Bogart G, Kloster M, Accurso F, Rosenfeld M, Albers G, Black P, Brown P, Cairns A, Davis SD, Graff GR, Kerby GS, Orenstein D, Buckingham R, Ramsey BW, et al. Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis: The Optimize Randomized Trial. American Journal of Respiratory and Critical Care Medicine. PMID 29890086 DOI: 10.1164/Rccm.201802-0215Oc |
0.453 |
|
| 2018 |
Rayment JH, Stanojevic S, Davis SD, Retsch-Bogart G, Ratjen F. Lung clearance index to monitor treatment response in pulmonary exacerbations in preschool children with cystic fibrosis. Thorax. PMID 29449440 DOI: 10.1136/Thoraxjnl-2017-210979 |
0.472 |
|
| 2017 |
Zemanick ET, Wagner BD, Robertson CE, Ahrens RC, Chmiel JF, Clancy JP, Gibson RL, Harris WT, Kurland G, Laguna TA, McColley SA, McCoy K, Retsch-Bogart G, Sobush KT, Zeitlin PL, et al. Airway microbiota across age and disease spectrum in cystic fibrosis. The European Respiratory Journal. 50. PMID 29146601 DOI: 10.1183/13993003.00832-2017 |
0.468 |
|
| 2017 |
Oude Engberink E, Ratjen F, Davis SD, Retsch-Bogart G, Amin R, Stanojevic S. Inter-test reproducibility of the lung clearance index measured by multiple breath washout. The European Respiratory Journal. 50. PMID 28982773 DOI: 10.1183/13993003.00433-2017 |
0.344 |
|
| 2017 |
Klingel M, Stanojevic S, Jensen R, Rosenfeld M, Davis S, Ratjen F, Retsch-Bogart G. Effect of reporting two versus three trials on lung clearance index values European Respiratory Journal. DOI: 10.1183/1393003.Congress-2017.Oa1792 |
0.339 |
|
| 2016 |
Stanojevic S, Davis SD, Retsch-Bogart G, Webster H, Davis M, Johnson RC, Jensen R, Pizarro ME, Kane M, Clem CC, Schornick L, Subbarao P, Ratjen FA. Progression of Lung Disease in Preschool Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine. PMID 27943680 DOI: 10.1164/Rccm.201610-2158Oc |
0.426 |
|
| 2016 |
Flume PA, Clancy JP, Retsch-Bogart GZ, Tullis DE, Bresnik M, Derchak PA, Lewis SA, Ramsey BW. Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 27233377 DOI: 10.1016/J.Jcf.2016.05.001 |
0.463 |
|
| 2016 |
Abode KA, Drake AF, Zdanski CJ, Retsch-Bogart GZ, Gee AB, Noah TL. A Multidisciplinary Children's Airway Center: Impact on the Care of Patients With Tracheostomy. Pediatrics. PMID 26755695 DOI: 10.1542/Peds.2015-0455 |
0.305 |
|
| 2016 |
Stanojevic S, Jensen R, Webser H, Kane M, Pizarro ME, Davis S, Retsch-Bogart G, Subbarao P, Ratjen F. Tracking pulmonary exacerbations in preschool children using the lung clearance index European Respiratory Journal. 48. DOI: 10.1183/13993003.Congress-2016.Oa1490 |
0.38 |
|
| 2015 |
Mayer-Hamblett N, Kloster M, Rosenfeld M, Gibson RL, Retsch-Bogart GZ, Emerson J, Thompson V, Ramsey BW. Impact of Sustained Eradication of New Pseudomonas aeruginosa Infection on Long-term Outcomes in Cystic Fibrosis. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 25972024 DOI: 10.1093/Cid/Civ377 |
0.416 |
|
| 2015 |
Faro A, Wood RE, Schechter MS, Leong AB, Wittkugel E, Abode K, Chmiel JF, Daines C, Davis S, Eber E, Huddleston C, Kilbaugh T, Kurland G, Midulla F, Molter D, ... ... Retsch-Bogart G, et al. Official American Thoracic Society technical standards: flexible airway endoscopy in children. American Journal of Respiratory and Critical Care Medicine. 191: 1066-80. PMID 25932763 DOI: 10.1164/Rccm.201503-0474St |
0.332 |
|
| 2014 |
Retsch-Bogart GZ, Van Dalfsen JM, Marshall BC, George C, Pilewski JM, Nelson EC, Goss CH, Ramsey BW. Highly effective cystic fibrosis clinical research teams: critical success factors. Journal of General Internal Medicine. 29: S714-23. PMID 25029977 DOI: 10.1007/S11606-014-2896-8 |
0.325 |
|
| 2014 |
Mayer-Hamblett N, Rosenfeld M, Gibson RL, Ramsey BW, Kulasekara HD, Retsch-Bogart GZ, Morgan W, Wolter DJ, Pope CE, Houston LS, Kulasekara BR, Khan U, Burns JL, Miller SI, Hoffman LR. Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes. American Journal of Respiratory and Critical Care Medicine. 190: 289-97. PMID 24937177 DOI: 10.1164/Rccm.201404-0681Oc |
0.435 |
|
| 2014 |
Mayer-Hamblett N, Ramsey BW, Kulasekara HD, Wolter DJ, Houston LS, Pope CE, Kulasekara BR, Armbruster CR, Burns JL, Retsch-Bogart G, Rosenfeld M, Gibson RL, Miller SI, Khan U, Hoffman LR. Pseudomonas aeruginosa phenotypes associated with eradication failure in children with cystic fibrosis. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 59: 624-31. PMID 24863401 DOI: 10.1093/Cid/Ciu385 |
0.486 |
|
| 2014 |
Tullis DE, Burns JL, Retsch-Bogart GZ, Bresnik M, Henig NR, Lewis SA, Lipuma JJ. Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: a placebo-controlled trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 13: 296-305. PMID 24176390 DOI: 10.1016/J.Jcf.2013.08.011 |
0.487 |
|
| 2013 |
Mayer-Hamblett N, Rosenfeld M, Treggiari MM, Konstan MW, Retsch-Bogart G, Morgan W, Wagener J, Gibson RL, Khan U, Emerson J, Thompson V, Elkin EP, Ramsey BW. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis. Pediatric Pulmonology. 48: 943-53. PMID 23818295 DOI: 10.1002/Ppul.22693 |
0.409 |
|
| 2012 |
Rowe SM, Borowitz DS, Burns JL, Clancy JP, Donaldson SH, Retsch-Bogart G, Sagel SD, Ramsey BW. Progress in cystic fibrosis and the CF Therapeutics Development Network. Thorax. 67: 882-90. PMID 22960984 DOI: 10.1136/Thoraxjnl-2012-202550 |
0.459 |
|
| 2012 |
Mayer-Hamblett N, Kronmal RA, Gibson RL, Rosenfeld M, Retsch-Bogart G, Treggiari MM, Burns JL, Khan U, Ramsey BW. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonology. 47: 125-34. PMID 21830317 DOI: 10.1002/Ppul.21525 |
0.427 |
|
| 2012 |
Burns J, LiPuma JJ, Retsch-Bogart G, Bresnik M, Henig N, McKevitt M, Lewis S, Tullis E. 58 No antibiotic cross-resistance after 1 year of continuous aztreonam for inhalation solution (AZLI) in cystic fibrosis (CF) patients (pts) with chronic Burkholderia (BURK) infection Journal of Cystic Fibrosis. 11. DOI: 10.1016/S1569-1993(12)60228-8 |
0.448 |
|
| 2012 |
Tullis E, Burns J, Retsch-Bogart G, Bresnik M, Henig N, Lewis S, LiPuma JJ. WS5.4 Aztreonam for inhalation solution (AZLI) in cystic fibrosis (CF) patients with chronic Burkholderia species (BURK) infection: final results from a randomized, placebo-controlled trial Journal of Cystic Fibrosis. 11. DOI: 10.1016/S1569-1993(12)60037-X |
0.454 |
|
| 2011 |
Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, Williams J, Hiatt P, Gibson RL, Spencer T, Orenstein D, Chatfield BA, Froh DK, Burns JL, Rosenfeld M, et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Pediatrics & Adolescent Medicine. 165: 847-56. PMID 21893650 DOI: 10.1001/Archpediatrics.2011.136 |
0.414 |
|
| 2011 |
Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson RL, McKevitt M, Montgomery AB. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI). The Journal of Antimicrobial Chemotherapy. 66: 2398-404. PMID 21784781 DOI: 10.1093/Jac/Dkr303 |
0.455 |
|
| 2011 |
Tullis E, Burns JL, Retsch-Bogart G, Bresnik M, Lewis S, Montgomery AB, LiPuma JJ. 84 Aztreonam 75 mg powder and solvent for nebuliser solution (AZLI) in cystic fibrosis (CF) patients with chronic Burkholderia species (Burk) infection: baseline demographics and microbiology from a randomized, placebo-controlled trial Journal of Cystic Fibrosis. 10. DOI: 10.1016/S1569-1993(11)60103-3 |
0.435 |
|
| 2010 |
Oermann CM, Retsch-Bogart GZ, Quittner AL, Gibson RL, McCoy KS, Montgomery AB, Cooper PJ. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatric Pulmonology. 45: 1121-34. PMID 20672296 DOI: 10.1002/Ppul.21301 |
0.503 |
|
| 2010 |
Rosenfeld M, Emerson J, McNamara S, Joubran K, Retsch-Bogart G, Graff GR, Gutierrez HH, Kanga JF, Lahiri T, Noyes B, Ramsey B, Ren CL, Schechter M, Morgan W, Gibson RL, et al. Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort. Pediatric Pulmonology. 45: 934-44. PMID 20597081 DOI: 10.1002/Ppul.21279 |
0.475 |
|
| 2010 |
Zemanick ET, Harris JK, Conway S, Konstan MW, Marshall B, Quittner AL, Retsch-Bogart G, Saiman L, Accurso FJ. Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 9: 1-16. PMID 19833563 DOI: 10.1016/J.Jcf.2009.09.003 |
0.485 |
|
| 2010 |
Treggiari M, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kronmal R, Ramsey B, Accurso F. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis Journal of Cystic Fibrosis. 9: S54. DOI: 10.1016/S1569-1993(10)60210-X |
0.444 |
|
| 2009 |
Retsch-Bogart GZ. Update on new pulmonary therapies. Current Opinion in Pulmonary Medicine. 15: 604-10. PMID 19696677 DOI: 10.1097/Mcp.0B013E328331805B |
0.426 |
|
| 2009 |
Sermet-Gaudelus I, Castanet M, Retsch-Bogart G, Aris RM. Update on cystic fibrosis-related bone disease: a special focus on children. Paediatric Respiratory Reviews. 10: 134-42. PMID 19651384 DOI: 10.1016/J.Prrv.2009.05.001 |
0.304 |
|
| 2009 |
Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials. 30: 256-68. PMID 19470318 DOI: 10.1016/J.Cct.2009.01.003 |
0.515 |
|
| 2009 |
Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS, Montgomery AB, Cooper PJ. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest. 135: 1223-32. PMID 19420195 DOI: 10.1378/Chest.08-1421 |
0.479 |
|
| 2009 |
Oermann C, McCoy K, Retsch-Bogart G, Gibson R, Quittner A, Montgomery A. Adherence over multiple courses of Aztreonam Lysine for Inhalation (AZLI): effect on disease-related endpoints in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA) Journal of Cystic Fibrosis. 8: S28. DOI: 10.1016/S1569-1993(09)60113-2 |
0.484 |
|
| 2009 |
McCoy K, Retsch-Bogart G, Gibson R, Oermann C, McKevitt M, Montgomery A. Efficacy of Aztreonam Lysine for Inhalation (AZLI) in patients with cystic fibrosis and drug resistant P. aeruginosa (DRPA) Journal of Cystic Fibrosis. 8: S28. DOI: 10.1016/S1569-1993(09)60112-0 |
0.383 |
|
| 2009 |
Oermann C, McCoy K, Retsch-Bogart G, Gibson R, Montgomery A. Effect of multiple courses of Aztreonam Lysine for Inhalation (AZLI) on FEV1 and weight in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA): Analysis of 18 month data from CP-AI-006 Journal of Cystic Fibrosis. 8: S28. DOI: 10.1016/S1569-1993(09)60111-9 |
0.454 |
|
| 2008 |
McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine. 178: 921-8. PMID 18658109 DOI: 10.1164/Rccm.200712-1804Oc |
0.528 |
|
| 2008 |
Retsch-Bogart GZ, Burns JL, Otto KL, Liou TG, McCoy K, Oermann C, Gibson RL. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatric Pulmonology. 43: 47-58. PMID 18041081 DOI: 10.1002/Ppul.20736 |
0.474 |
|
| 2008 |
McCoy K, Retsch-Bogart G, Gibson R, Oermann C, Braff M, Montgomery A. Microbiologic resistance and clinical efficacy of aztreonam lysine for inhalation (AZLI) in cystic fibrosis (CF) Journal of Cystic Fibrosis. 7: S36. DOI: 10.1016/S1569-1993(08)60138-1 |
0.439 |
|
| 2008 |
Oermann C, McCoy K, Retsch-Bogart G, Gibson R, Quittner A, Montgomery A. Effect of multiple aztreonam lysine for inhalation (AZLI) cycles on disease-related endpoints and safety in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA): Interim analysis of 12 month data Journal of Cystic Fibrosis. 7: S25. DOI: 10.1016/S1569-1993(08)60097-1 |
0.467 |
|
| 2007 |
Treggiari MM, Rosenfeld M, Retsch-Bogart G, Gibson R, Ramsey B. Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Pediatric Pulmonology. 42: 751-6. PMID 17647287 DOI: 10.1002/Ppul.20665 |
0.504 |
|
| 2007 |
Gibson RL, Emerson J, Mayer-Hamblett N, Burns JL, McNamara S, Accurso FJ, Konstan MW, Chatfield BA, Retsch-Bogart G, Waltz DA, Acton J, Zeitlin P, Hiatt P, Moss R, Williams J, et al. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatric Pulmonology. 42: 610-23. PMID 17534969 DOI: 10.1002/Ppul.20625 |
0.443 |
|
| 2007 |
Davis SD, Fordham LA, Brody AS, Noah TL, Retsch-Bogart GZ, Qaqish BF, Yankaskas BC, Johnson RC, Leigh MW. Computed tomography reflects lower airway inflammation and tracks changes in early cystic fibrosis. American Journal of Respiratory and Critical Care Medicine. 175: 943-50. PMID 17303797 DOI: 10.1164/Rccm.200603-343Oc |
0.421 |
|
| 2007 |
McCoy K, Retsch-Bogart G, Oermann C, Gibson R, Montgomery A. 40* Aztreonam lysine for inhalation (AZLI) for CF patients with P. aeruginosa (PA) infection Journal of Cystic Fibrosis. 6: S10. DOI: 10.1016/S1569-1993(07)60033-2 |
0.45 |
|
| 2006 |
Gibson RL, Retsch-Bogart GZ, Oermann C, Milla C, Pilewski J, Daines C, Ahrens R, Leon K, Cohen M, McNamara S, Callahan TL, Markus R, Burns JL. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatric Pulmonology. 41: 656-65. PMID 16703579 DOI: 10.1002/Ppul.20429 |
0.513 |
|
| 2005 |
Deterding R, Retsch-Bogart G, Milgram L, Gibson R, Daines C, Zeitlin PL, Milla C, Marshall B, Lavange L, Engels J, Mathews D, Gorden J, Schaberg A, Williams J, Ramsey B, et al. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis. Pediatric Pulmonology. 39: 339-48. PMID 15704203 DOI: 10.1002/Ppul.20192 |
0.381 |
|
| 2005 |
Moss RB, Mayer-Hamblett N, Wagener J, Daines C, Hale K, Ahrens R, Gibson RL, Anderson P, Retsch-Bogart G, Nasr SZ, Noth I, Waltz D, Zeitlin P, Ramsey B, Starko K. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. Pediatric Pulmonology. 39: 209-18. PMID 15573395 DOI: 10.1002/Ppul.20152 |
0.384 |
|
| 2003 |
Ordoñez CL, Henig NR, Mayer-Hamblett N, Accurso FJ, Burns JL, Chmiel JF, Daines CL, Gibson RL, McNamara S, Retsch-Bogart GZ, Zeitlin PL, Aitken ML. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine. 168: 1471-5. PMID 12969869 DOI: 10.1164/Rccm.200306-731Oc |
0.381 |
|
| 2003 |
Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Waltz D, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine. 167: 841-9. PMID 12480612 DOI: 10.1164/Rccm.200208-855Oc |
0.423 |
|
| 2002 |
Egan TM, Detterbeck FC, Mill MR, Bleiweis MS, Aris R, Paradowski L, Retsch-Bogart G, Mueller BS. Long term results of lung transplantation for cystic fibrosis. European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association For Cardio-Thoracic Surgery. 22: 602-9. PMID 12297180 DOI: 10.1016/S1010-7940(02)00376-7 |
0.365 |
|
| 2001 |
Rosenfeld M, Gibson R, McNamara S, Emerson J, McCoyd KS, Shell R, Borowitz D, Konstan MW, Retsch-Bogart G, Wilmott RW, Burns JL, Vicini P, Montgomery AB, Ramsey B. Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis. The Journal of Pediatrics. 139: 572-7. PMID 11598606 DOI: 10.1067/Mpd.2001.117785 |
0.424 |
|
| 1996 |
Schechter MS, Retsch-Bogart GZ, Margolis PA. RELATIONSHIP BETWEEN INSURANCE COVERAGE AND DISEASE SEVERITY IN CYSTIC FIBROSIS PATIENTS UNDER 21 YEARS OF AGE. † 655 Pediatric Research. 39: 112-112. DOI: 10.1203/00006450-199604001-00677 |
0.365 |
|
| Show low-probability matches. |
